search
Back to results

A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)

Primary Purpose

Dementia With Lewy Bodies, Alzheimer's Disease, Parkinson's Disease

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
18F-AV-133
18F-AV-45
Sponsored by
Avid Radiopharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Dementia With Lewy Bodies

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria DLB:

  • Male or female > 50 years of age
  • Meet the diagnostic criteria for probable DLB as established by the DLB Consortium (McKeith et al., 2005)

Inclusion Criteria AD:

  • Male or female > 50 years of age
  • Meet the NINCDS criteria for probable AD and have a Mini Mental State Examination (MMSE) score at screening between 10 and 24 inclusive

Inclusion Criteria PD:

  • Male or female > 50 years of age
  • Have probable PD according to the following criteria (Gelb et al., 1999):

    • Presence of 2 of the following 3 features: rest tremor, rigidity, bradykinesia;
    • Documented history of a sustained (>6 months) improvement to Levodopa (L-DOPA) or a dopamine agonist
    • Absence of atypical clinical features or other possible signs or symptoms suggesting another cause of parkinsonism such as a history of frequent falls as a prominent early feature, localized brain lesion(s) or neuroleptic use
    • Asymmetric onset
  • A diagnosis of PD made within the 4 years prior to enrollment

Normal subjects:

  • Are males or females > 50 years of age
  • Have a MMSE score > 29, and are cognitively normal on the psychometric test battery at screening
  • Have no signs or symptoms of clinically meaningful parkinsonism

Exclusion Criteria:

  • Have a history or current diagnosis of other neurologic disease
  • Have evidence of clinically significant cerebrovascular disease
  • Have evidence from MRI or other biomarker studies that suggests the presence of a CNS pathology other than that associated with the study diseases

Sites / Locations

  • Research Site
  • Research Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Other

Other

Other

Other

Arm Label

Dementia with Lewy Bodies

Parkinson's disease

Healthy Elderly Volunteers

Alzheimer's Disease

Arm Description

Outcomes

Primary Outcome Measures

18F-AV-133 striatal to occipital standard uptake value ratio
The ratio of tracer activity in striatal target areas of interest relative to the occipital cortex reference region

Secondary Outcome Measures

18F-AV-45 cortical to cerebellar standard uptake value ratio
The ratio of tracer activity in cortical target areas of interest relative to the cerebellum reference region

Full Information

First Posted
July 14, 2010
Last Updated
August 3, 2012
Sponsor
Avid Radiopharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT01503944
Brief Title
A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)
Official Title
Detection of Striatal Dopaminergic Degeneration and Neocortical Amyloid Pathology in Patients With Dementia With Lewy Bodies, Alzheimer's Disease, Parkinson's Disease, and Healthy Elderly Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
August 2012
Overall Recruitment Status
Completed
Study Start Date
March 2010 (undefined)
Primary Completion Date
July 2011 (Actual)
Study Completion Date
July 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Avid Radiopharmaceuticals

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the ability to identify individuals with dopaminergic degeneration in group of patients with a clinical diagnosis of either dementia with Lewy bodies (DLB) or idiopathic Parkinson's disease and to differentiate them from Alzheimer's disease (AD) and control subjects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dementia With Lewy Bodies, Alzheimer's Disease, Parkinson's Disease

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Dementia with Lewy Bodies
Arm Type
Other
Arm Title
Parkinson's disease
Arm Type
Other
Arm Title
Healthy Elderly Volunteers
Arm Type
Other
Arm Title
Alzheimer's Disease
Arm Type
Other
Intervention Type
Drug
Intervention Name(s)
18F-AV-133
Intervention Description
185 MBq
Intervention Type
Drug
Intervention Name(s)
18F-AV-45
Intervention Description
185-370 MBq
Primary Outcome Measure Information:
Title
18F-AV-133 striatal to occipital standard uptake value ratio
Description
The ratio of tracer activity in striatal target areas of interest relative to the occipital cortex reference region
Time Frame
Four Weeks
Secondary Outcome Measure Information:
Title
18F-AV-45 cortical to cerebellar standard uptake value ratio
Description
The ratio of tracer activity in cortical target areas of interest relative to the cerebellum reference region
Time Frame
Four Weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria DLB: Male or female > 50 years of age Meet the diagnostic criteria for probable DLB as established by the DLB Consortium (McKeith et al., 2005) Inclusion Criteria AD: Male or female > 50 years of age Meet the NINCDS criteria for probable AD and have a Mini Mental State Examination (MMSE) score at screening between 10 and 24 inclusive Inclusion Criteria PD: Male or female > 50 years of age Have probable PD according to the following criteria (Gelb et al., 1999): Presence of 2 of the following 3 features: rest tremor, rigidity, bradykinesia; Documented history of a sustained (>6 months) improvement to Levodopa (L-DOPA) or a dopamine agonist Absence of atypical clinical features or other possible signs or symptoms suggesting another cause of parkinsonism such as a history of frequent falls as a prominent early feature, localized brain lesion(s) or neuroleptic use Asymmetric onset A diagnosis of PD made within the 4 years prior to enrollment Normal subjects: Are males or females > 50 years of age Have a MMSE score > 29, and are cognitively normal on the psychometric test battery at screening Have no signs or symptoms of clinically meaningful parkinsonism Exclusion Criteria: Have a history or current diagnosis of other neurologic disease Have evidence of clinically significant cerebrovascular disease Have evidence from MRI or other biomarker studies that suggests the presence of a CNS pathology other than that associated with the study diseases
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chief Medical Officer
Organizational Affiliation
Avid Radiopharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Research Site
City
Sun City
State/Province
Arizona
Country
United States
Facility Name
Research Site
City
Philadelphia
State/Province
Pennsylvania
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)

We'll reach out to this number within 24 hrs